Tezepelumab Anti-TSLP (thymic stromal lymphopoietin) Treatment of severe asthma
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Tezepelumab Anti-TSLP (thymic stromal lymphopoietin) Treatment of severe asthma. / Yao, Y.; Ali, Z.; Thomsen, S. F.
In: Drugs of the Future, Vol. 46, No. 7, 2021, p. 529-536.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Tezepelumab Anti-TSLP (thymic stromal lymphopoietin) Treatment of severe asthma
AU - Yao, Y.
AU - Ali, Z.
AU - Thomsen, S. F.
PY - 2021
Y1 - 2021
N2 - Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine of the interleukin-2 (IL-2) cytokine family with both homeostatic and inflammatory properties in the human organism. Aberrant production of TSLP has been observed in several type 2 allergic disorders such as bronchial asthma, atopic dermatitis and allergic rhinitis, prompting the development of anti-TSLP agents. In this review, we present the current known pharmacodynamics, pharmacokinetics, efficacy, safety and ongoing trials of tezepelumab. Tezepelumab (AMG-157, MEDI-9929) is a fully human immunoglobulin G subclass 2 (lgG2)anti-TSLP monoclonal antibody under investigation for the treatment of moderate to severe asthma. A phase 11 study has concluded that subcutaneously administered tezepelumab at doses of 210 mg every 4 weeks reduces exacerbation rates of asthma other than the type 2 endotype, improves lung function in asthmatic patients, and reduces levels of biomarkers of type 2 inflammation. Tezepelumab was generally well-tolerated with an acceptable safety profile and low rate of serious adverse events and discontinuations due to adverse events.
AB - Thymic stromal lymphopoietin (TSLP) is an epithelial-derived cytokine of the interleukin-2 (IL-2) cytokine family with both homeostatic and inflammatory properties in the human organism. Aberrant production of TSLP has been observed in several type 2 allergic disorders such as bronchial asthma, atopic dermatitis and allergic rhinitis, prompting the development of anti-TSLP agents. In this review, we present the current known pharmacodynamics, pharmacokinetics, efficacy, safety and ongoing trials of tezepelumab. Tezepelumab (AMG-157, MEDI-9929) is a fully human immunoglobulin G subclass 2 (lgG2)anti-TSLP monoclonal antibody under investigation for the treatment of moderate to severe asthma. A phase 11 study has concluded that subcutaneously administered tezepelumab at doses of 210 mg every 4 weeks reduces exacerbation rates of asthma other than the type 2 endotype, improves lung function in asthmatic patients, and reduces levels of biomarkers of type 2 inflammation. Tezepelumab was generally well-tolerated with an acceptable safety profile and low rate of serious adverse events and discontinuations due to adverse events.
KW - Tezepelumab
KW - AMG-157
KW - MEDI-9929
KW - TSLP
KW - Asthma
KW - Atopic dermatitis
KW - Biologics
KW - Pharmacokinetics
KW - Clinical study
KW - GENOME-WIDE ASSOCIATION
KW - IGM(+) B-CELLS
KW - UNCONTROLLED ASTHMA
KW - IN-VITRO
KW - PHARMACOKINETICS
KW - DIFFERENTIATION
KW - TOLERABILITY
KW - PHENOTYPE
KW - CYTOKINE
KW - SAFETY
U2 - 10.1358/dof.2021.46.7.3301491
DO - 10.1358/dof.2021.46.7.3301491
M3 - Journal article
VL - 46
SP - 529
EP - 536
JO - Drugs of the Future
JF - Drugs of the Future
SN - 0377-8282
IS - 7
ER -
ID: 274871668